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Forkhead box K2 modulates epirubicin and paclitaxel
sensitivity through FOXO3a in breast cancer
G Nestal de Moraes1,2, P Khongkow1, C Gong1,3, S Yao1, AR Gomes1, Z Ji4, N Kandola1, D Delbue1,2, EPS Man3, US Khoo3,
AD Sharrocks4 and EW-F Lam1
The forkhead transcription factor FOXK2 has recently been implicated in cancer cell proliferation and survival, but a role in cancer
chemotherapeutic drug resistance has hitherto not been explored. Here we demonstrate that FOXK2 has a central role in mediating
the cytotoxic drug response in breast cancer. Clonogenic and cell viability assays showed that enhanced FOXK2 expression
sensitizes MCF-7 breast cancer cells to paclitaxel or epirubicin treatment, whereas FOXK2 depletion by small interfering RNAs
(siRNAs) confers drug resistance. Our data also showed that the activation of the tumour suppressor FOXO3a by paclitaxel and
epirubicin is mediated through the induction of FOXK2, as depletion of FOXK2 by siRNA limits the induction of FOXO3a by these
drugs in MCF-7 cells. Chromatin immunoprecipitation (ChIP) analysis showed that in response to drug treatment, FOXK2
accumulates and binds to the proximal FOXO3a promoter region in MCF-7 cells. Furthermore, we also uncovered that FOXK2 is
deregulated and, therefore, can express at high levels in the nucleus of both the paclitaxel and epirubicin drug-resistant MCF-7
cells. Our results showed that ectopically overexpressed FOXK2 accumulates in the nuclei of drug-resistant MCF-7 cells but failed to
be recruited to target genes, including FOXO3a. Crucially, we found that FOXO3a is required for the anti-proliferative and
epirubicin-induced cytotoxic function of FOXK2 in MCF-7 cells by sulphorhodamine and clonogenic assays. The physiological
importance of the regulation of FOXO3a by FOXK2 is further conﬁrmed by the signiﬁcant correlations between FOXO3a and FOXK2
expression in breast carcinoma patient samples. Further survival analysis also reveals that high nuclear FOXK2 expression
signiﬁcantly associates with poorer clinical outcome, particularly in patients who have received conventional chemotherapy,
consistent with our ﬁnding that FOXK2 is deregulated in drug-resistant cells. In summary, our results suggest that paclitaxel and
epirubicin target the FOXK2 to modulate their cytotoxicity and deregulated FOXK2 confers drug resistance.
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INTRODUCTION
Forkhead box K (FOXK) proteins are a subgroup of the Forkhead
transcription factors, characterized by a conserved DNA-
binding domain1 known to regulate a diverse range of biological
processes, such as differentiation, survival, metabolism,
senescence, apoptosis and cell cycle progression.2 FOXK2 is one
of the two FOXK isoforms in mammals and was ﬁrst identiﬁed as a
NFAT-like interleukin-binding factor.3 Compared with the related
FOXK1, little is known about the biological function and
mechanism of regulation of FOXK2. It has been demonstrated
that FOXK2 can be phosphorylated by cyclin/CDK complexes in a
cell cycle-dependent manner.4 FOXK2 has also been shown to
associate with AP-1 transcription factor to modify chromatin, thus
enabling AP-1 binding to its target genes.5,6 In that study,
genome-wide Chromatin immunoprecipitation (ChIP)-seq
analysis shows that FOXK2 can regulate a wide range of gene
networks, particularly those involved in cell adhesion and motility,
metabolism and, interestingly, apoptosis and cancer.5,6 Recently, it
has been reported that FOXK2 can interact with the polycomb
complex molecules and recruit the BAP-1 tumour suppressor
protein to the chromatin,6,7 further conﬁrming that FOXK2 might
function in modifying the chromatin structure.
Paclitaxel and epirubicin belong to the taxane and anthracy-
cline classes of chemotherapeutic agents, respectively. Although
these drugs are highly effective and commonly used for the
management of breast cancer, chemoresistance commonly arises
and accounts for treatment failure. Deregulation of expression and
activity of some of the tumour-suppressive FOX transcription
factors, such as FOXO3a, has been linked extensively to breast
cancer initiation and progression, as well as drug resistance.8,9
FOXO3a has a crucial role in mediating the cytotoxic effects
of chemotherapeutic agents in breast cancer through the
modulation of downstream transcriptional targets.10 It has been
demonstrated that FOXO3a expression and nuclear translocation
are induced in response to paclitaxel11,12 and doxorubicin
treatment,13 suggesting that enhancing FOXO3a activity might
potentiate the sensitivity of breast cancer cells to chemotherapy.10
However, there is hitherto no description of the role of FOXK2 in
breast cancer drug resistance and that it is not known whether
FOXK2 is modulated following treatment with chemotherapeutic
agents. Considering these observations, we speculated that FOXK2
could have a role in drug resistance in breast cancer. We show
here that FOXK2 regulates FOXO3a to modulate drug sensitivity
and that deregulation of expression and activity of FOXK2 confers
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paclitaxel and epirubicin resistance and associates with a poor
clinical outcome in breast carcinoma patients.
RESULTS
FOXK2 is differentially expressed in drug-sensitive and -resistant
breast cancer cell lines
Recent evidence suggests that FOXK2 may have a role in cancer
development.4,14 However, the regulation and expression of
FOXK2 in breast cancer and its role in drug resistance have
hitherto not been explored. To address this, we ﬁrst compared the
expression patterns of FOXK2 in MCF-7 cells and its drug-resistant
counterparts MCF-7TaxR and MCF-7EpiR cell lines. Western blotting
analysis showed that FOXK2 is expressed consistently at higher
levels in the paclitaxel- and epirubicin-resistant cells compared
with the parental MCF-7 cells (Figure 1a). We next examined its
expression in the wild-type and resistant MCF-7 cells in response
to paclitaxel and epirubicin treatment, respectively. Although
FOXK2 expression was low in MCF-7 cells, it was induced in
response to paclitaxel and epirubicin treatment and then declined
at later time points (Figure 1b; Supplementary Figure S1), most
likely due to global protein degradation as a result of cell
death.15–19 By contrast, FOXK2 expression was constitutively high
and remained unchanged in the resistant cell lines following
paclitaxel and epirubicin treatment (Figure 1b). Conversely,
quantitative real-time PCR (qRT–PCR) analysis revealed that FOXK2
mRNA levels were consistently low in the resistant cell lines
compared with sensitive MCF-7 cells (Figure 1c). Corroborating the
protein data, FOXK2 mRNA levels were modulated upon paclitaxel
and epirubicin treatment of MCF-7, but remained stable in the
resistant cell lines (Figure 1c). Together, these results suggest that
there are distinct differences in FOXK2 expression patterns in
drug-sensitive and -resistant cell lines, with FOXK2 protein
inducible by both paclitaxel and epirubicin in the drug-
sensitive MCF-7 cells but not the resistant cells. The data also
show that FOXK2 expression in drug-sensitive and -resistant
MCF-7 cell lines is not primarily regulated at the transcriptional
levels. We also obtained results to suggest that FOXK2 is
predominantly located in the nucleus of breast cancer cell lines,
regardless of their drug resistance and treatment (Supplementary
Figures S2 and S3).
FOXK2 depletion promotes resistance to paclitaxel and epirubicin
in breast cancer cells
To investigate the role of FOXK2 in breast cancer drug resistance,
FOXK2 expression was depleted using small interfering RNA
(siRNA) in both sensitive and resistant cell lines, which were then
treated with a range of concentrations of the chemotherapeutic
drugs and assayed for their drug response through short- and
long-term cell viability assays. Sulphorhodamine (SRB) assays
showed that FOXK2-silenced MCF-7 cells were more resistant to
both paclitaxel (Figure 2a, upper panel) and epirubicin (Figure 2b,
upper panel). In the MCF-7TaxR and MCF-7EpiR resistant cell lines,
we observed no effect of FOXK2 knockdown on drug response
(Figures 2a and b, lower panels). Corroborating these data, there
was an increase in the colony-formation capacity of FOXK2-
depleted MCF-7 cells, particularly at 0.5 and 1 nM of paclitaxel and
0.05 and 0.1 μM of epirubicin treatment (Figures 3a and b, left
panels). In agreement, we could not observe any changes in the
colony-formation capacity of resistant cell lines in response to
drug treatment (Figures 3a and b, right panels).
FOXK2 regulates FOXO3a expression in drug-sensitive breast
cancer cells
Previous studies demonstrated that FOXK2 cross-talks with the
tumour suppressor FOXO3a to regulate cell proliferation
and survival.20 Given that FOXO3a has been shown to mediate
the cytostatic and cytotoxic functions of taxanes and
anthracyclines,11,12,15,21 together these ﬁndings led us to hypothe-
size that FOXK2 might target FOXO3a expression to induce
breast cancer cell proliferation arrest and cell death in response to
these conventional anticancer chemotherapeutics. To test
this conjecture, we investigated FOXO3a expression following
FOXK2 knockdown. The results showed that FOXK2 depletion
resulted in a reduction of FOXO3a expression in the paclitaxel-
sensitive MCF-7 but not in the resistant MCF-7TaxR cells
(Figure 4a; Supplementary Figure S4). We also analysed the
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Figure 1. FOXK2 expression in sensitive and drug-resistant breast
cancer cell lines. (a) MCF-7, MCF-7TaxR and MCF-7EpiR were
harvested and their lysates subjected to western blot analysis,
where FOXK2 and β-tubulin levels were determined. (b) MCF-7 and
MCF-7TaxR were treated with 10 nM paclitaxel for 0, 8, 16, 24, 48 and
72 h (upper panel). MCF-7 and MCF-7EpiR were treated with 1 μM
epirubicin for 0, 4, 8, 16, 24 and 48 h (lower panel). Cells were
collected and subjected to western blot analysis. FOXK2 and
β-tubulin levels were determined. (c) MCF-7 and MCF-7TaxR were
exposed to 10 nM paclitaxel for 0, 8, 16, 24, 48 and 72 h (upper
panel). MCF-7 and MCF-7EpiR were exposed to 1 μM epirubicin for 0,
4, 8, 16, 24 and 48 h (lower panel). The levels of FOXK2 mRNA
transcript were determined by qRT–PCR after normalization against
L19. Bars represent average± s.d..
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expression of cyclin B1 and Polo-like kinase 1 (PLK1), targets
known to be repressed by FOXO3a.22 Consistently, cyclin B1
and PLK1 were found to be upregulated in FOXK2-depleted
MCF-7 cells, especially at 24 h after paclitaxel treatment
(Figure 4a). We also found that FOXK2 knockdown resulted
in downregulation in FOXO3a mRNA levels in MCF-7 cells,
indicative of the transcriptional regulation of FOXO3a by
FOXK2 (Figure 4b). By comparison, we did not observe substantial
changes in FOXO3a and its downstream targets in the resistant
MCF-7TaxR cells upon FOXK2 depletion, suggesting FOXK2
is deregulated in the MCF-7TaxR cells (Figures 4a and b).
Together these results suggest that FOXK2 knockdown promotes
paclitaxel and epirubicin resistance, which might involve the
modulation of FOXO3a expression.
Overexpression of FOXK2 enhances FOXO3a expression to
sensitize breast cancer cells to paclitaxel
We next overexpressed FOXK2 and examined its effects on
paclitaxel resistance. Consistent with FOXK2 knockdown results,
our short-term viability data show that FOXK2-overexpressing
MCF-7 cells displayed a more sensitive phenotype towards
paclitaxel than cells transfected with the empty vector
(Figure 5a, upper panel). To further conﬁrm this result, we
performed clonogenic assay and observed that, at 0.5 and 1 nM
of paclitaxel, FOXK2 overexpression could also inhibit the
colony-formation capacity of MCF-7 cells in response to paclitaxel
(Figure 5b, left panel). Interestingly, induction of FOXK2
overexpression in MCF-7TaxR resistant cells could not sensitize
them to paclitaxel treatment, as examined by both short- and
long-term cell viability assays (Figure 6a, lower panel and
Figure 6b, right panel). To investigate whether the lack of effect
of FOXK2 overexpression on sensitizing MCF-7TaxR cells to
paclitaxel was a result of mislocalization of wild-type FOXK2, we
analysed FOXK2 localization in sensitive and resistant cells and
found that FOXK2 was localized predominantly in the nucleus of
both MCF-7 and MCF-7TaxR cells (Supplementary Figure S5).
This result indicates that the differences in effects of FOXK2
overexpression in sensitive and resistant breast cancer cell lines
are not owing to deregulated FOXK2 subcellular localization. We
next studied the effects of FOXK2 overexpression on FOXO3a
protein and mRNA expression levels, as well as its subcellular
localization. Our results showed that FOXK2 overexpression
caused an induction of FOXO3a protein (Figure 6a) and mRNA
(Figure 6b) levels in MCF-7, but not in MCF-7TaxR cells,
further conﬁrming that FOXK2 regulates FOXO3a expression in
paclitaxel-sensitive cells. Consistently, the levels of FOXO3a
transcription factor were increased in the nucleus of
FOXK2-overexpressing MCF-7 cells (Figure 6c). By contrast,
FOXO3a nuclear expression levels remained low in the
MCF-7TaxR resistant cells, where we observed no effect of FOXK2
overexpression on drug response. To further conﬁrm the role of
FOXK2 in paclitaxel sensitivity and response, we overexpressed
FOXK2 in the moderately paclitaxel-resistant MDA-MB-231 breast
cancer cells (Supplementary Figure S6a) and found the FOXK2-
overexpressing MDA-MB-231 cells were more sensitive to
paclitaxel treatment compared with control MDA-MB-231 cells
(Supplementary Figure S6b) and had decreased colony-formation
capacities in response to paclitaxel (Supplementary Figure S6c).
Consistently, these effects were associated with upregulation of
FOXO3a at the protein and mRNA levels (Supplementary Figures
S6d and S6e). Conversely, knockdown of FOXK2 in MDA-MB-231
cells by using siRNA also resulted in the cells becoming more
resistant to paclitaxel (Supplementary Figure S7). Collectively,
these ﬁndings suggest that FOXK2 targets FOXO3a expression in
breast cancer cells to enhance sensitivity to paclitaxel.
FOXK2 regulates FOXO3a expression through a forkhead response
element in its promoter
Analysis of a recently published ChIP-sequencing data revealed that
in U2OS cells, FOXK2 is recruited to the promoter region of the
human FOXO3a gene, containing a forkhead response element
(FHRE;5 Figure 7a). We therefore next investigated whether FOXK2
regulates FOXO3a expression directly through binding to the
FOXO3a promoter. For this purpose, we studied the occupancy of
the FHRE region of the FOXO3a promoter by FOXK2 using ChIP in
MCF-7 cells in response to paclitaxel treatment. Our results
showed that the binding of FOXK2 to the FHRE region of the
FOXO3a promoter increased in response to paclitaxel treatment in
MCF-7 cells (Figure 7b). Corroborating our previous data, only low
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Figure 2. FOXK2 depletion promotes resistance to paclitaxel and
epirubicin in sensitive but not resistant breast cancer cells. (a) MCF-7
and MCF-7TaxR transfected with NSC (non-silencing control)
and FOXK2 siRNA independently were seeded in 96-well plates
and treated with increasing concentrations of paclitaxel for 24, 48
and 72 h. Viability was measured by SRB assay. (b) MCF-7 and
MCF-7EpiR transfected with NSC and FOXK2 siRNA were seeded in
96-well plates and treated with increasing concentrations of
epirubicin for 24, 48 and 72 h. Viability was measured by SRB assay
and compared between NSC and FOXK2 siRNA samples. The graphs
are representative of three experiments. Statistical signiﬁcance was
determined by Student’s t-test (two-sided; *P⩽ 0.05, **P⩽ 0.01,
signiﬁcant).
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levels of FOXK2 binding were detected on the endogenous FOXO3a
promoter in MCF-7TaxR cells either at basal levels or following
paclitaxel treatment (Figure 7b), further conﬁrming that FOXK2 is
unable to drive FOXO3a expression in paclitaxel-resistant cells. In
agreement, treatment with 5 nM of paclitaxel provoked a substantial
induction of FOXO3a expression at the protein and mRNA levels in
MCF-7, but not MCF-7TaxR cells (Figures 7c and d). We also analysed
the expression of PLK1 and cyclin B1 as downstream targets of
FOXO3a and found that their expression was downregulated
particularly at 24 h post-paclitaxel treatment, when FOXO3a
expression increased. To further conﬁrm our ﬁndings on the
regulation of FOXO3a expression by FOXK2, we overexpressed
FOXK2 in both MCF-7 and MCF-7TaxR cell lines and analysed its
recruitment to the FOXO3a promoter FHRE by RT–qPCR following
ChIP. Our RT–qPCR results showed that overexpression of FOXK2
caused an increase in FOXK2 binding to the FOXO3a promoter in
MCF-7 cells (Figure 7e). In addition, the binding of FOXK2 to
FOXO3a promoter was further enhanced by paclitaxel treatment,
conﬁrming that FOXK2 transcriptional activity is inducible by drug
treatment. In contrast, there were no signiﬁcant increases in the
recruitment of FOXK2 to the FOXO3a promoter in MCF-7TaxR cells
following FOXK2 overexpression, suggesting that FOXK2 is
deregulated and inactive in the resistant cells. Together, these
data show that FOXK2 can directly bind to the FOXO3a promoter
and regulate its expression in the paclitaxel-sensitive, but not the
resistant, breast cancer cells.
FOXK2 restricts cell proliferation and enhances drug sensitivity
through targeting FOXO3a
FOXO3a has been shown to mediate the cytotoxic function of
anthracyclines, including epirubicin, and, therefore, likely has a
central role in mediating the anti-proliferative function of FOXK2.
To test this idea, we overexpressed FOXK2 in MCF-7 cells with or
without FOXO3a depletion (Figure 8a) and tested their effects on
cell proliferation upon epirubicin treatment. More speciﬁcally, the
proliferation rate and clonogenicity of these transfected MCF-7
cells in response to a range of epirubicin concentrations were
monitored by SRB and clonogenic assays, respectively. The cell
proliferation assays showed that overexpression of FOXK2 or
FOXO3a depletion signiﬁcantly limited MCF-7 cell proliferation
compared with the control MCF-7 cells, transfected with non-
silencing siRNA pool and the empty expression vector (Figure 8b;
Supplementary Figure S8a). This is somewhat unexpected as
FOXO3a is a well-established tumour suppressor;2,9 however, it has
also been shown to have a role in cell renewal and expansion.23,24
Despite the fact that both FOXK2 overexpression and FOXO3a
depletion independently repressed cell proliferation, MCF-7 cells
with simultaneous FOXK2 overexpression and FOXO3a depletion
displayed similar proliferative rates as the cells with FOXO3a
silenced only, suggesting that FOXO3a is essential for the
anti-proliferative function of FOXK2. The result showed that
overexpression of FOXK2 signiﬁcantly increases the sensitivity of
MCF-7 cells to epirubicin (Figure 8a and Supplementary Figure
NSC FOXK2 siRNA
Paclitaxel:
(nM)
NSC FOXK2 siRNA
MCF-7 MCF-7 TaxR
R
el
at
iv
e 
ce
ll 
vi
ab
ili
ty
NSC FOXK2 siRNA
Epirubicin:
(μM)
NSC FOXK2 siRNA
MCF-7 MCF-7EpiR
0 0.05 0.1
Paclitaxel (nM) Paclitaxel (nM)
R
el
at
iv
e 
ce
ll 
vi
ab
ili
ty
Epirubicin (μM) Epirubicin (μM)
***
***
0 0.5 1
3 5 10
0 0.5 1
3 5 10
0 0.5 1
3 5 10
0 0.5 1
3 5 10
0 0.05 0.1
0.5 1 5 0.5 1 1
0 0.05 0.1 0 0.05 0.1
5 0.5 5 0.5 1 5
NSC siRNA
FOXK2 siRNA
NSC siRNA
FOXK2 siRNA
**
**
Figure 3. FOXK2 depletion promotes resistance to paclitaxel and epirubicin in sensitive but not resistant breast cancer cells. (a) MCF-7 and
MCF-7TaxR cells and (b) MCF-7 and MCF-7EpiR cells were transfected with NSC (non-silencing control) and FOXK2 siRNA, seeded in six-well
plates and treated with increasing concentrations of paclitaxel. After 48 h of incubation with the drugs, cells were cultured in fresh media,
grown for around 14 days and stained with crystal violet. The graphs are representative of three experiments. Statistical signiﬁcance was
determined by Student’s t-test (two-sided; **P⩽ 0.01, ***P⩽ 0.001, signiﬁcant).
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S8a). Furthermore, we also found that FOXK2 overexpression
enhanced the sensitivity of MCF-7 cells to epirubicin but had
no appreciable anti-proliferative effects on MCF-7 cells with
FOXO3a depleted in terms of drug sensitivity (Figure 8b and
Supplementary Figure S8b). Consistently, clonogenic assays also
revealed that although FOXK2 ectopic expression could potentiate
the cytotoxic function of epirubicin in the control MCF-7 cells with
FOXO3a expression, FOXK2 overexpression had no signiﬁcant
effects in MCF-7 cells with FOXO3a depleted (Figures 8c and d).
Together these results indicate that FOXO3a is a key target of
FOXK2 and that FOXO3a mediates the anti-proliferative effects
and cytotoxic function of FOXK2 in response to epirubicin.
FOXK2 nuclear expression correlates with FOXO3a expression and
clinical outcome in breast cancer patients
To ascertain further the physiological and clinical importance of
the regulation of FOXO3a by FOXK2 in breast cancer, FOXO3a and
FOXK2 expression was assessed by immunohistochemistry in 86
invasive ductal carcinoma patient samples, of which 46 received
anthracyclin and taxane chemotherapy treatment (Figure 9a;
Supplementary Figure S10). Consistent with our ﬁnding from the
breast cancer cell lines that FOXK2 expresses primarily in the
nucleus, all the patients had predominantly nuclear FOXK2
expression. Statistical analysis of the immunohistochemical results
revealed that nuclear, but not cytoplasmic or total, FOXK2
expression is marginally correlated with total FOXO3a expression
(Pearson coefﬁcient r= 0.238, *P= 0.054; *P⩽ 0.05 = signiﬁcant) in
all the invasive ductal carcinoma cases (Figure 9a; Supplementary
Figure S9). However, nuclear FOXK2 was strongly and signiﬁcantly
associated with total FOXO3a (Pearson coefﬁcient r= 0.378,
**P= 0.014; **P⩽ 0.01, very signiﬁcant) in patients that received
chemotherapy (Figure 9a; Supplementary Figure S8). This
corroborates the ﬁnding from the breast cancer cell lines and
further suggests that FOXK2 directly regulates FOXO3a transcrip-
tion. Moreover, nuclear FOXK2 expression was also signiﬁcantly
correlated with oestrogen receptor status and tumour stage
(Supplementary Figure S11). Further survival analysis showed that
nuclear and total FOXK2 expression was associated with overall
survival but not statistically signiﬁcant (Kaplan–Meier analysis;
log-rank test, P= 0.078 and P= 0.058, respectively; Figure 9b;
Supplementary Figure S12). However, of all invasive ductal
carcinoma patients, nuclear and total FOXK2 expression was
signiﬁcantly correlated with disease-speciﬁc survival (log-rank test,
*P= 0.048 and *P= 0.049, respectively; Figure 9b; Supplementary
Figure S12). Of patients that received chemotherapy, elevated
nuclear and total FOXK2 was signiﬁcantly associated with
poorer outcome (log-rank test, *P= 0.029 and *P= 0.048 for
overall survival, and *P= 0.040 and *P= 0.045 for disease-speciﬁc
survival, respectively; Figure 9c; Supplementary Figure S12). The
signiﬁcance of FOXK2 in survival analyses provides further
evidence for its involvement in breast cancer progression and
drug response. These results are in accordance with our in vitro
observations of overexpression of FOXK2 in drug-resistant cell
lines and further suggest that constitutively high expression levels
of nuclear FOXK2 is associated with drug resistance and poor
clinical outcome.
DISCUSSION
The development of drug resistance is a major obstacle to
successful cancer chemotherapy and is associated with limited
therapeutic options and poorer prognosis in cancer patients.
Recent evidence has linked FOXK2 to cancer cell proliferation and
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Figure 4. Depletion of FOXK2 transcription factor results in FOXO3a downregulation. (a) MCF-7 and MCF-7TaxR were harvested and subjected
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survival,25 but hitherto, a role in cancer chemotherapeutic drug
resistance has not been established. In this study, we examined
the role and regulation of FOXK2 in mediating the cell
proliferation and chemotherapeutic drug response in breast
cancer. We identiﬁed FOXK2 as a key mediator of the cytotoxic
function of paclitaxel and epirubicin as well as a modulator of
drug sensitivity in breast cancer. In the presence of paclitaxel or
epirubicin treatment, clonogenic and cell viability assays showed
that enhanced expression of FOXK2 inhibits cell proliferation and
clonogenic growth of the drug-sensitive MCF-7 breast carcinoma
cells. Conversely, FOXK2 depletion by siRNA increased cell viability
and clonogenicity, and conferred resistance to these conventional
cancer chemotherapeutic agents in MCF-7 cells. Notably, although
FOXK2 depletion or overexpression causes profound changes in
cell proliferation and viability in MCF-7 cells upon paclitaxel and
epirubicin treatment, it has little effect in untreated MCF-7 cells.
This suggests that the ability of FOXK2 to modulate paclitaxel
and epirubicin sensitivity is not merely a reﬂection of the
anti-proliferative function of FOXK2.
Our results also reveal that FOXK2 controls FOXO3a expression
in response to paclitaxel and epirubicin. Our data show that
FOXO3a activation by paclitaxel and epirubicin is mediated
through the induction of FOXK2, as depletion of FOXK2 by siRNA
impairs the induction of FOXO3a by paclitaxel and epirubicin in
MCF-7 cells. Consistent with previous observations,4,14 we show
that FOXK2 is predominantly expressed in the nucleus, regardless
of their drug resistance and treatment. Upon treatment with these
cytotoxic agents, we found that FOXK2 remains in the nucleus,
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Figure 5. Overexpression of wild-type FOXK2 sensitizes MCF-7 cells to paclitaxel treatment. (a) MCF-7 and MCF-7TaxR cells were transfected
with the empty vector (pCMV5) and the wild-type FOXK2 vector, seeded in 96-well plates and treated with increasing concentrations of
paclitaxel. After 24, 48 and 72 h of incubation with the drugs, cell viability was assessed by SRB assay. (b) MCF-7 and MCF-7TaxR were
transfected with the empty vector (pCMV5) and the wild-type FOXK2 vector, seeded in six-well plates and treated with increasing
concentrations of paclitaxel. After 48 h of incubation with the drugs, cells were cultured in fresh media, grown for around 14 days and stained
with crystal violet. The graphs are representative of three experiments. Statistical signiﬁcance was determined by Student’s t-test (two-sided;
*P⩽ 0.05, **P⩽ 0.01, ***P⩽ 0.001, signiﬁcant).
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and this is associated with the induction of FOXO3a transcription
and expression in MCF-7 and MDA-MB-231 cells. We also show by
ChIP experiments that the FOXO3a promoter is a direct target of
FOXK2 and binding is accompanied by or associated with FOXO3a
expression and proliferative arrest. Together these results suggest
that conventional chemotherapeutic agents, including anthracy-
clines and taxanes, induces FOXK2 to accumulate in the nucleus,
where it induces the expression of downstream targets, including
FOXO3a, a crucial mediator of the cytotoxic and cytostatic actions
of anticancer chemotherapeutic agents in breast cancer cells13,15
(Supplementary Figure S13). Furthermore, we also uncovered that
FOXK2 is deregulated in both the paclitaxel and epirubicin
drug-resistant MCF-7 cells and consequently can accumulate
at high levels in these cells. Accordingly, cytoplasmic/nuclear
protein fractionation, confocal microscopy and ChIP experiments
revealed that ectopically overexpressed wild-type FOXK2 protein
accumulates in the nucleus of the drug-resistant MCF-7TaxR and
MCF-7EpiR cells but fails to be recruited to the target gene
FOXO3a. This inability of FOXK2 to be recruited to its target genes,
such as FOXO3a, is likely to occur at the post-translation levels.
Alternatively, this can also be that the target genes are not
accessible to FOXK2 as a result of epigenetic changes in the
resistant cells. Indeed, post-translational modiﬁcations have
previously been shown to modulate the transcriptional activity
of FOXK2. For example, FOXK2 has been shown to be
phosphorylated by cyclin-dependent kinases (CDKs) and
hyperphosphorylated FOXK2 is less stable.4 However, the CDK-
mediated phosphorylation is unlikely to be responsible for the
inactivation of FOXK2 in the drug-resistant cells as FOXK2 is
overexpressed but inactive in the drug-resistant cells.
The physiological relevance of the regulation of FOXO3a by
FOXK2 is further underscored by the signiﬁcant correlations
between FOXO3a and FOXK2 expression in invasive ductal breast
carcinoma patient samples. Intriguingly, survival analysis reveals
that nuclear FOXK2 expression signiﬁcantly associates with poorer
clinical outcome, particularly in patients that have received
conventional chemotherapy. This observation is in line with our
ﬁndings in the paclitaxel- and epirubicin-resistant MCF-7 cells that
in the drug-resistant breast cancer cells, the high levels of nuclear
FOXK2 are deregulated and inactive, which will ultimately impact
on chemotherapeutic drug response and patient survival.
Collectively, our results suggest that FOXK2 mediates the cytotoxic
drug response and functions as a tumour suppressor, which is
often deregulated in drug-resistant cancer cells. However, FOXK2
has also been proposed to be required for cell proliferation.14 The
reason for this apparent discrepancy is unclear but it could be that
the cell models used in this study are mostly untransformed cells.
Conversely, in concordance with our ﬁndings, ectopic
FOXK2 expression has been shown to induce apoptosis in the
osteosarcoma U2OS cells.4 Moreover, FOXK2 has also been shown
to recruit BAP-1, an important tumour suppressor, to the
chromatin and to promote local deubiquitination during DNA
damage response.6
FOXM1 is a forkhead box transcription factor transcriptionally
repressed by FOXO3a, which has been demonstrated to be a key
modulator of the anticancer therapeutics, including taxanes and
anthracylines.10,26–29 Accordingly, FOXM1 has been shown to
confer genotoxic agent resistance through promoting the
expression of targets, including NBS1 (Nebrin), XRCC1, BRCA2,
CHEK1 (CHK1), RAD51 and BRIP1,15,17,30,31 important for DNA
damage signalling and repair, to limit the genotoxic effects.
In addition, FOXM1 can also promote resistance to taxanes
and other mitotic modulators through driving the expression of
the microtubulin-associated kinesins, such as KIF20A, at the
transcriptional level.19 In consequence, FOXO3a can impact
the cytotoxic function of FOXK2 through down-modulating
FOXM1 transcription and activity.10 Thus, FOXK2 deregulation
can lead to FOXO3a downregulation and FOXM1 overexpresssion.
In agreement, FOXM1 has been demonstrated to be expressed at
constitutively high levels in the MCF-7TaxR and MCF-7EpiR cells
where FOXK2 is deregulated.16–19
In summary, our ﬁndings suggest that paclitaxel and epirubicin
target the FOXK2-FOXO3a axis to modulate their cytotoxic
function and deregulated FOXK2 may confer drug resistance.
We also present compelling evidence to show that drug-resistant
breast cancer cells are able to tolerate high levels of nuclear
FOXK2 because FOXK2 is deregulated and fails to be recruited to
targets genes, such as FOXO3a. These data provide novel insights
into the underlying mechanisms of chemotherapy resistance and
have implications for the development of predictive biomarkers
and novel chemotherapeutic strategies for drug resistance.
MATERIALS AND METHODS
Cell culture
The human breast cancer cell lines MCF-7 and MDA-MB-231 originated
from the American Type Culture Collection (Manassas, VA, USA) and were
acquired from the Cell Culture Service from Cancer Research UK, where
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Figure 6. FOXK2 overexpression upregulates FOXO3a expression.
(a) MCF-7 and MCF-7TaxR cells were collected following FOXK2
overexpression and subjected to western blot analysis, where FOXK2,
FOXO3a and β-tubulin levels were determined. (b) MCF-7 and
MCF-7TaxR cells were transfected with the empty vector (pCMV5)
and the wild-type FOXK2 vector sequences and exposed to 10 nM
paclitaxel for 0, 6 and 24 h. The levels of FOXO3a and FOXM1 mRNA
transcript were determined by qRT–PCR after normalization against
L19. Bars represent average± s.d. from three independent experi-
ments. Statistical signiﬁcance was determined by Student’s t-test
(*P⩽ 0.05, signiﬁcant). (c) MCF-7 and MCF-7TaxR were treated with
10 nM paclitaxel for 0 and 6 h and harvested for subcellular
fractionation. Afterwards, cytoplasmic (cyt) and nuclear (nuc)
fractions were subjected to western blot analysis, and FOXK2,
β-tubulin (cytoplasmic loading control) and Lamin B (nuclear loading
control) levels were determined. NS, not signiﬁcant.
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they were authenticated. The cell lines were cultured in Dulbecco’s
modiﬁed Eagle’s medium supplemented with 10% fetal calf serum,
100 U/ml penicillin/streptomycin and 2mM glutamine and maintained
in a humidiﬁed incubator with 10% CO2 at 37 °C. The MCF-7Tax
R and
MCF-7EpiR resistant cell lines were originated from MCF-7 and maintained
in 50 nM paclitaxel and 17 μM doxorubicin, respectively.16
Plasmids
The plasmids encoding human FOXK2 pCMV5-FOXK2WT and the empty
vector pCMV5 have previously been described.4 Expression plasmid
transfections were performed with FuGENE 6 (Roche, IN, USA), according
to manufacturers’ instructions. The cells were collected and seeded for
drug treatment following 24 h of transfection.
Western blot and antibodies
Western blotting was done in whole-cell extracts prepared by lysing cells
in lysis buffer as previously described.21 The antibodies recognizing FOXK2
(A301-729A) and total FOXO3a (07-702) were purchased from Bethyl Labs
(Cambridge Bioscience Ltd, Cambridge, UK) and Millipore (Hertfordshire,
UK), respectively. Cyclin B1 (sc-752), PLK1 (sc-17783), Lamin B (sc-6217) and
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Figure 7. FOXK2 binds to the FOXO3a promoter in MCF-7 cells. (a) Chromatin immunoprecipitation (ChIP) analysis of FOXO3a promoter. A pair
of primers amplifying the forkhead responsive elements (FHRE)-binding-site-containing FOXO3a promoter region (-1066/-907 bp) was
designed. (b) MCF-7 and MCF-7TaxR treated with 5 nM paclitaxel for 0, 2, 4, 8 and 24 h were used for chromatin immunoprecipitation assays
using the IgG as negative control and anti-FOXK2 antibody. After reversal of cross-linking, the co-immunoprecipitated DNA was ampliﬁed by
qRT–PCR, using primers amplifying the FOXK2 binding-site-containing region. (c) MCF-7 and MCF-7TaxR cells were exposed to 5 nM paclitaxel
for 0, 2, 4, 8 and 24 h and the levels of FOXO3a mRNA transcript were determined by qRT–PCR after normalization against L19. Bars represent
average± s.d. from two independent experiments. (d) After treatment of MCF-7 and MCF-7TaxR cells with 5 nM paclitaxel for 0, 2, 4, 8 and 24 h,
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MCF-7TaxR cells transfected with the empty vector (pCMV5) and wild-type FOXK2 were used for chromatin immunoprecipitation assays using
the IgG as negative control and anti-FOXK2 antibody. After reversal of cross-linking, the co-immunoprecipitated DNA was ampliﬁed by qRT–
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Student's t-test (*P⩽ 0.05, ****P⩽ 0.005; ns., non-signiﬁcant).
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β-tubulin (sc-9104) antibodies were obtained from Santa Cruz Biotechnol-
ogy (Santa Cruz; Insight Biotechnology, Middlesex, UK). Primary antibodies
were detected using horseradish peroxidase-linked anti-mouse, anti-rabbit
or anti-goat conjugates (Dako, Glostrup, Denmark) and visualized using the
ECL detection system (PerkinElmer, Coventry, UK).
Quantitative real-time PCR
The extraction of total RNA was performed with the RNeasy Mini Kit (Qiagen,
Hilden, Germnay) and complementary DNA was synthetized by the
Superscript III Method (Invitrogen, Paisley, UK), according to manufacturers’s
instructions. Transcript levels were analysed by qRT–PCR using the standard
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Figure 8. FOXO3a is required for the anti-proliferative and epirubicin-induced cytotoxic function of FOXK2. MCF-7 cells were transiently
transfected with either the control pCMV or FOXK2 and non-silencing control (NSC) siRNA or the FOXO3a siRNA smart pool. (a) Twenty-four
hours after transfection, protein lysates were prepared from these cells and then analysed for the expression of FOXK2, FOXO3a and β-tubulin
(b) The transfected cells were also treated with a range of doses of epirubicin (0–5000 nM) and their proliferative rates assayed by SRB assay at
48 and 72 h after epirubicin treatment. Statistical signiﬁcance was determined by Student’s t-test (two-sided; *P⩽ 0.05, **P⩽ 0.01, NS, not
signiﬁcant) by comparing the proliferation rates of cells transfected with pFOXK2 with the control pCMV transfected cells. (c) Twenty-four
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average of three independent experiments± s.d. Statistical signiﬁcance was determined by Student’s t-test (two-sided; *P⩽ 0.05, **P⩽ 0.01,
NS, not signiﬁcant).
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curve and normalized to ribosomal protein L19 mRNA levels, as
previously described.32 The forward and reverse primers used were: L19-F:
5′-GCGGAAGGGTACAGCCAAT-3′ and L19-R: 5′-GCAGCCGGCGCAAA-3′,
FOXK2-F: 5′-AGTCTCCAGTGAAGGCCGTA-3′ and FOXK2-R: 5′-CCCACCTTG
TACCCTGAAGA-3′ and FOXO3a-F: 5′-TCTACGAGTGGATGGTGCGTT-3′ and
FOXO3a-R: 5′- CGACTATGCAGTGACAGGTTGTG-3′.
Gene silencing with siRNAs
For FOXK2 knockdown, cells were transfected with siRNA SMART pool
reagents (Thermo Scientiﬁc Dharmacon; Life Technologies, Paisley, UK)
using Oligofectamine (Invitrogen) based on manufacturer’s recommenda-
tions. SMARTPool siRNAs used here were as follows: siRNA FOXK2
(L-008354-00-0010) and the non-silencing control siRNA (D-001810-10-50).
ChIP assay
Following paclitaxel treatment and FOXK2 overexpression, cells were
collected for the chromatin immunoprecipitation (ChIP) assay as previous
described.19 The reaction was run in 7900 HT Fast Real-time PCR System
(Applied Biosystems, Life Technologies Ltd, Paisley, UK) and the cycling
programme was 95 °C for 10min followed by 40 cycles of 95 °C for 15 s,
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Figure 9. Positive correlation between FOXK2 and FOXO3a expression in breast cancer patients. (a) FOXK2 and FOXO3a expression was
assessed by immunohistochemistry using tissue-microarray constructed from 116 breast cancer patient samples. Representative staining
images of one patient with high FOXK2 and FOXO3a expression and one with low expression are shown. Magniﬁcation: Images (×20) and
Insets (×100). FOXK2 was expressed predominantly in the nucleus, while FOXO3a staining were detected in both nuclear and cytoplasmic
compartments. Positive correlation between nuclear FOXK2 and total FOXO3a expression was observed. Statistical analysis revealed that
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60 °C for 30 s and 95 °C for 30 s, followed by a dissociation step. The pair of
primers used for ChIP was: FOXO3a-F, 5′-ACCAACATCTTCGCCGTTC-3′ and
FOXO3a-R, 5′-GGTGTCCGGTTCCCTGTTAG-3′, Each sample was assayed in
triplicates, and the results were normalized to the IgG antibody.
SRB assay
For the assessment of short-term changes in cell viability in drug-treated
cells following FOXK2 knockdown and overexpression, we performed the
SRB assay. Brieﬂy, 3000 cells were seeded in 96-well plates and left to
adhere for 24 h, after which paclitaxel or epirubicin was added and cells
were maintained in culture for an additional 24, 28 and 72 h. Cells were
then ﬁxed with 100 μl of 40% trichloroacetic acid for 1 h at 4 °C, washed
three times with distilled water and stained with 100 μl SRB solution (0.4%
SRB diluted in 1% acetic acid) for 1 h. Afterwards, the plates were washed
three times with 1% acetic acid and air-dried. Protein-bound dye was
solubilized in 100 μl of 10mM Tris solution and optical density was
measured in a microplate reader at 492 nm (Sunrise, Tecan, Dorset, UK).
Clonogenic assay
For clonogenic assay, a total of 2000 MCF-7 and MCF-7EpiR cells or 5000
MCF-7 and MCF-7TaxR cells were seeded into six-well plates and left
overnight for adherence, after which they were treated with increasing
concentrations of paclitaxel and epirubicin as described.19,33 After 48 h of
incubation with the drugs, cells were cultured in fresh drug-free media and
grown for ~ 14 days when colonies were formed. The colonies were
washed three times with phosphate-buffered saline and ﬁxed with 4%
formaldehyde for 15min at room temperature. After three additional
washes with phosphate-buffered saline, the colonies were stained with
0.5% crystal violeta (Sigma-Aldrich UK, Poole, UK) for 1 h, washed with
ﬂowing water and air-dried. Then, 1 ml of 33% acetic acid was added to
each well for crystal violet solubilization and optical density was measured
at 592 nm using a microplate reader (Sunrise, Tecan, Dorset, UK).
Tissue microarray, immunohistochemistry and staining scoring
These reagents and analyses have previously been described.19,33 For
details, see Supplementary Materials and Methods.
Statistical analysis
Statistical analyses of data were conducted using the SPSS Statistics
software (SPSS for Windows, version 17.0, SPSS Inc., IBM, London, UK).
The Student’s t-test was used to compare the differences between means
from the two groups. The values of *Po0.05, **Po0.01 and ***Po0.005
were considered statistically signiﬁcant. The Kaplan–Meier method was
used to assess survival, which was compared between groups using the
log-rank test. The association between FOXK2 and FOXO3a expression and
clinical-pathological parameters was analysed by the chi-square test. A
value of Po0.05 was considered statistically signiﬁcant.
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